Melatonin Use Linked to Reduced Risk for Development, Progression of AMD

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on June 11, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, June 11, 2024 -- Melatonin use is associated with a reduced risk for development and progression of age-related macular degeneration (AMD), according to a study published online June 6 in JAMA Ophthalmology.

Hejin Jeong, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues conducted a retrospective cohort study to examine the association between melatonin supplementation and the risk for development or progression of AMD. Melatonin medication codes were queried for patients aged 50 years or older, 60 years or older, and 70 years or older with no history of AMD (AMD-naive group) and with a history of nonexudative AMD (nonexudative AMD group). Based on the presence of medication codes for melatonin, patients were then classified into a melatonin group or control group.

The researchers found that among 121,523 patients aged 50 years or older in the AMD-naive cohort and 116,675 in the control cohort (4,580 in each group after propensity score matching), melatonin use was associated with a reduced risk for developing AMD (risk ratio [RR], 0.42). Melatonin was associated with a reduced risk of AMD progression to exudative AMD (RR, 0.44) among 66,253 patients aged 50 years or older in the nonexudative AMD group and 61,903 controls (4,064 in each group after propensity score matching). Among subsets of patients aged 60 years or older and 70 years or older, the findings were similar.

"Given the convenient availability in oral form and generally benign safety profile of melatonin, confirmation of this study's results in future clinical trials and longitudinal studies could contribute to advancing the current treatment options for AMD," the authors write.

Two authors disclosed ties to the pharmaceutical and eye health care industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-06-12 01:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords